H-Optimus-0 outperforms rivals, redefining biological research
Bioptimus has raised $76 million—including a recent $41M round led by Cathay Innovation—to advance its mission of building the world’s first universal AI foundation model for biology.
Its first release, H-Optimus-0, is already the largest pathology AI model globally. It has surpassed benchmarks from Harvard Medical School and the University of Leeds, demonstrating standout capabilities like gene expression prediction and ovarian cancer subtyping from tissue morphology.
Bioptimus aims to break the silos of traditional biological research by integrating multi-scale and multi-modal data—from molecules to organisms, and from imaging to genomics. CEO Jean-Philippe Vert describes the platform as “the GPT of biology” for its ability to simulate complex biological systems.
The funding will support AI model refinement, dataset expansion, and industry partnerships, driving cross-sector breakthroughs from pharma to cosmetics.
Follow MEDWIRE.AI for the latest in AI-driven life sciences.
